Pharma Update

Growing portfolio in malignant hematology Hematologic tumor cases by subtype1 Ph III clinical development overview On-market portfolio 3% 12% Pipeline molecules Lunsumic 9% cevostamab 7% COLUMVI glofitamab forimtamig 14% Rituxan Rituximab GAZYVA obinutuzumab injection VENCLEXTA™ venetoclax tablets 50 100 POLIVY polatuzumab vedotin P-BCMA-ALLO1** IL15/IL15Ra-Fc Phl Ph II Columvi + chemo (STARGLO) in 2L+ DLBCL Lunsumio + Polivy (SUNMO) in 2L+ DLBCL Lunsumio + lenalidomide (CELESTIMO) in 2L+ FL Ph Ill 37% CD19 x CD28 Venclexta + azacitidine (VERONA) in 1L MDS Englumafusp alfa 17% Venclexta + dexamethasone (CANOVA) in t(11;14) R/R MM MM iNHL* DLBCL MDS AML CLL ALL Further potential to grow our hematology franchise: Taking Columvi and Lunsumio into earlier lines, as well as 6 NMEs into new indications 1 Datamonitor: incidence rates includes the 7 major markets (US, Japan, France, Germany, Italy, Spain, UK); *including FL; **In collaboration with Poseida Therapeutics; MM-Multiple myeloma; iNHL-indolent non-hodgkin's lymphoma; DLBCL=Diffuse large B-cell lymphoma; MDS-Myelodysplastic syndromes; AML=Acute myeloid leukemia; CLL=Chronic lymphocytic leukemia; NHL=Non-hodgkin's lymphoma; FL=Follicular Lymphoma Roche 57

View entire presentation